Exact Sciences Corp (EXAS) Acquired by Abbott: Key Details for Investors

Overview

Exact Sciences Corporation (NASDAQ: EXAS) has filed a Form 8-K with the SEC announcing the completion of its acquisition by Abbott Laboratories. This is a significant development with substantial implications for shareholders, affecting the company’s listing status, its corporate structure, and the rights of existing shareholders.

Key Points from the 8-K Filing

• Merger Completion: On March 23, 2026, the merger between Exact Sciences Corp and an Abbott Laboratories subsidiary (Merger Sub) was completed. Exact Sciences now operates as a direct, wholly owned subsidiary of Abbott.
• Shareholder Treatment: At the effective time of the merger, each share of Exact’s common stock (except for certain excluded and dissenting shares) was converted into the right to receive the “Per Share Merger Consideration” as specified in the merger agreement. Shareholders no longer have rights in Exact Sciences as a standalone public entity, except for the right to receive the merger consideration or, for dissenters, as determined under Delaware law.
• Delisting from Nasdaq: Trading in Exact’s common stock on the Nasdaq Stock Market was halted prior to the market opening on March 23, 2026. The company has requested Nasdaq to file for removal of listing and registration of its common stock, and intends to file Form 15 to suspend SEC reporting obligations.
• Material Change in Control: This transaction constitutes a change in control; Exact is now fully controlled by Abbott Laboratories.
• Amendments to Corporate Charter: At the effective time of the merger, Exact’s certificate of incorporation and bylaws were amended and restated as per the merger agreement, aligning the company’s governance with that of Abbott.
• Convertible Senior Notes: The filing notes the existence of 0.3750% Convertible Senior Notes due 2027, with further details available in the exhibits.

What Shareholders Need to Know

• Cash Out of Shares: Ordinary shareholders will be cashed out at the merger consideration price. They will no longer hold equity in the independent Exact Sciences entity, and the stock will cease trading.
• No Further Reporting: Exact will suspend its SEC reporting, meaning shareholders and the market will no longer receive regular financial and operational updates from the company as a standalone entity.
• Impact on Share Value: The value of EXAS shares is now defined by the cash merger consideration. There is no longer any market-based price movement, and share trading is halted.
• Dissenting Shareholders: Those who dissented to the merger may pursue remedies under Delaware law but will not receive the standard merger consideration until their process concludes.
• Convertible Notes: Holders of convertible notes should refer to the supplemental indentures filed as exhibits for information on conversion rights post-merger, as these may be paid in cash or otherwise adjusted per the merger agreement.
• Change in Governance: The board, bylaws, and all governance structures have been altered to reflect Abbott’s control.

Potentially Price-Sensitive or Market-Moving Information

• Delisting from Nasdaq: Effective immediately, EXAS shares are no longer publicly traded, which will eliminate liquidity for shareholders who have not yet tendered their shares.
• Final Payout: The amount received by shareholders will be as stated in the merger agreement, which should have been communicated previously. There is no further upside potential in EXAS as a public stock.
• Convertible Securities: Noteholders should review the supplemental indentures for details on their treatment, as this could impact the payout for these securities.
• Strategic Implications: Exact becomes part of Abbott, and any future value creation accrues to Abbott shareholders, not to former EXAS shareholders.

Conclusion

This filing marks the end of Exact Sciences as an independent public company. All trading in the stock ceases, and shareholders are entitled to the merger consideration. Any future developments in the company’s business or in the acquired assets will impact Abbott and its shareholders, not holders of the former EXAS stock.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should review the official SEC filings and consult with a financial advisor for guidance specific to their situation.

View EXACT SCIENCES CORP Historical chart here